4Moving Biotech announces the equity investment of the Arthritis Foundation to support the clinical development of its disease-modifying osteoarthritis drug candidate
4Moving Biotech, a spin-off of 4P-Pharma focusing on the development of 4P004, a first-in-class Disease Modifying OsteoArthritis Drug (DMOAD) announces the equity investment of the Arthritis Foundation to support the clinical development of its disease-modifying osteoarthritis drug candidate. “We are very pleased with the commitment of the Foundation Arthritis. Patients have always been the core of our&hellip